Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer.
Expression of the chemokine CXCL14 has previously been shown to be elevated in the tumour stroma of, for example, prostate and breast cancer. Cancer-associated fibroblast-derived CXCL14 enhances tumour growth in mouse models of prostate and breast cancer. However, the prognostic significance of compartment-specific expression of CXCL14 has not been studied.



CXCL14 mRNA expression was analysed in a breast cancer tissue microarray (TMA) of formalin-fixed, paraffin-embedded tumours by the RNAscope 2.0 Assay. Epithelial and stromal expression was analysed separately and correlated with clinicopathological characteristics and survival.



CXCL14 was variably and independently expressed in malignant and stromal cells of breast cancer. Total and stromal expression of CXCL14 did not associate with clinicopathological parameters. Epithelial CXCL14 expression was significantly associated with oestrogen receptor α (ERα)-positive tumours and lower proliferation status. Total CXCL14 expression correlated significantly with shorter breast cancer-specific and recurrence-free survival. High stromal, but not epithelial, CXCL14 expression was significantly associated with shorter survival in univariable and multivariable analyses. Moreover, the correlation between stromal CXCL14 expression and survival was more prominent in ER negative, triple negative and basal-like breast cancers.



The identification of prognostic significance of stromal CXCL14 in breast cancer demonstrates novel clinical relevance of a stroma-derived secreted factor and illustrates the importance of tumour compartment-specific analyses. On the basis of the prognostic signals from difficult-to-treat subgroups, CXCL14 should also be considered as a candidate drug target.
Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, 171 76 Stockholm, Sweden.
Elin
E
Sjöberg
Division for Vascular Oncology and Metastasis, German Cancer Research Center (DKFZ), 691 20 Heidelberg, Germany.
Martin
M
Augsten
Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet and Radiumhemmet-Karolinska Oncology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Jonas
J
Bergh
Division of Oncology and Pathology, Department of Clinical Sciences, Lund University 221 85, Lund, Sweden.
Karin
K
Jirström
Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, 171 76 Stockholm, Sweden.
Arne
A
Östman
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D019743:Chemokines, CXC / Q000235:genetics*; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology*; D016019:Survival Analysis
D014408:Biomarkers, Tumor; C118056:CXCL14 protein, human; D019743:Chemokines, CXC